论文部分内容阅读
目的分析稳定期慢性阻塞性肺疾病(COPD)治疗中布地奈德/福莫特罗粉剂联合噻托溴铵的临床应用效果。方法 90例处于稳定期的COPD患者,按照数字法随机分为对照组和研究组,每组45例。对照组采用布地奈德/福莫特罗粉剂吸入治疗,研究组在对照组基础上联合噻托溴铵吸入治疗,对比两组患者的临床治疗效果。结果治疗后3个月,研究组1 s内用力呼气容积(FEV1)、1 s内用力呼气容积与预期值的比例(FEV1%)、1 s内用力呼气容积与肺活量比例(FEV1/FVC)指标恢复情况明显优于对照组,差异具有统计学意义(P<0.05)。治疗后研究组氧分压(Pa O2)为(78.2±1.25)mm Hg(1 mm Hg=0.133 kPa)、二氧化碳分压(Pa CO2)为(58.8±1.57)mm Hg指标恢复情况明显优于对照组(77.4±1.55)、(59.6±1.69)mm Hg,差异具有统计学意义(P<0.05)。结论稳定期COPD治疗中布地奈德/福莫特罗粉剂联合噻托溴铵的临床应用效果明显,适合于临床推广。
Objective To analyze the clinical effect of budesonide / formoterol powder combined with tiotropium in the treatment of patients with chronic obstructive pulmonary disease (COPD) in stable phase. Methods Ninety patients with stable COPD were randomly divided into control group and study group according to the digital method, with 45 cases in each group. The control group was treated with inhaled budesonide / formoterol. The study group was treated with tiotropium inhalation on the basis of the control group, and the clinical effect of the two groups was compared. Results FEV1, FEV1%, FEV1 / FEV1, FEV1 and FEV1 in 1 s were significantly higher in study group than those in control group FVC) index recovery was significantly better than the control group, the difference was statistically significant (P <0.05). After treatment, the PaO2 was (78.2 ± 1.25) mm Hg (1 mm Hg = 0.133 kPa) and the PaCO2 was (58.8 ± 1.57) mm Hg, and the recovery was significantly better than that of the control Group (77.4 ± 1.55), (59.6 ± 1.69) mm Hg, the difference was statistically significant (P <0.05). Conclusion The clinical application of budesonide / formoterol powder combined with tiotropium in stable COPD is effective and is suitable for clinical promotion.